Efficacy and safety of oral vitamin D (cholecalciferol) supplement therapy in Stage I primary hypertension; a prospective, randomized, double-blind, placebo controlled, clinical trial in a tertiary care hospital in central India.

Manali Mahajan, Swapnil Deshmukh, Sujata Dudhgaonkar

Abstract


Introduction: Hypertension is one of the most common cardiovascular disorders. Almost all targets in its therapy are exploited and there is a growing need to search for newer targets. Vitamin D is gaining increasing attention in treatment of primary hypertension.

Objectives: To study the efficacy and safety of Vitamin D supplementation on systolic and diastolic BP in patients of primary hypertension (JNC 7 stage I) receiving conventional antihypertensive medications (namely Tab atenolol 50mg or Tab amlodipine 5mg).

Methods: It was a prospective, randomized, double blind, parallel, placebo controlled clinical trial with 2 groups of 33 patients each. Both groups had patients receiving conventional antihypertensives (Tab atenolol 50mg or Tab amlodipine 5mg). Group A patients were given placebo (lactose tablets) and Group B were given oral Vitamin D3 (60,000 IU) once weekly at bedtime after meals, repeated every fortnightly for 12 weeks.

Results: Patients belonging to Group B showed a statistically significant (p < 0.0001) decline in both systolic blood pressure after 12 weeks of receiving vitamin D supplementation. There was no significant change in the safety parameters.

Conclusions: Thus, our study shows that Vitamin D supplementation has some role in safely reducing systolic blood pressure after 12 weeks of supplementation and hence it should be supplemented with antihypertensive drugs to the patients with hypertension.


Keywords


Vitamin D, Hypertension, Amlodipine, Atenolol

Full Text:

PDF

References


. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007; 20:713–719.

. Benowitz NL. Antihypertensive Agents. In: Katzung BG, editor. Basic and Clinical Pharmacology, 12th edition, Chap 11, New York: McGraw-Hill; 2012; p. 167,168,183.

. Martins D, Wolf M, Pan D. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007; 167:1159–1165.

. Pfeifer M, Begerow B, Minne WH, Nachtigall D, Hansen C. Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab.2001; 86:1633–1637.

. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110: 229–238.

. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726-76.

. Li YC. 31. Molecular mechanism of vitamin D in the cardiovascular system. J Investig Med 2011; 59: 868-71.

. Fitzpatrick LA, Bilezikian JP, Silverberg SJ. 32. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep 2008; 6: 77-83.

. Brewer LC, Michos ED, Reis JP. 40. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets 2011; 12: 54-60.

. Tare M, Emmett SJ, Coleman HA, Skordilis C, Eyles DW, Morley R, et al. Vitamin D insufficiency is associated with impaired vascular endothelial and smooth muscle function and hypertension in young rats. J Physiol 2011; 589: 4777-86.




DOI: http://dx.doi.org/10.7439/ijpr.v7i6.4206

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 International Journal of Pharmacological Research

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.